Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 26INDUSTRY 9NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Lymphoid 9Myeloid 4Other neoplasm 2Sarcoma 1Plasma cell 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 35Doxorubicin 30Ifosfamide 29Cyclophosphamide 24Vincristine 23Filgrastim 23Etoposide 20Temozolomide 14Granulocyte Colony-Stimulating Factor 14Dactinomycin 11Cisplatin 11Trabectedin 10Methotrexate 10Gene Expression Profiling 10Radiation 9Imatinib Mesylate 9Surgical Procedures, Operative 8Polymerase Chain Reaction 8Irinotecan 8Specimen Handling 7Paclitaxel 7Chemotherapy, Adjuvant 7Mesna 6Immunohistochemistry 6Gemcitabine 6Carmustine 6Biopsy 6sargramostim 5pegfilgrastim 5etoposide phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × fludarabine × Sarcoma × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡